Immunology leader Mark Eisner joins Jade Biosciences (NASDAQ: JBIO) board
Rhea-AI Filing Summary
Jade Biosciences, Inc. filed an 8-K announcing that its Board appointed Mark Eisner, M.D., M.P.H., as a Class I director effective June 25, 2026. He will serve until the 2028 annual meeting and join the Nominating and Corporate Governance Committee.
Dr. Eisner brings more than 25 years of leadership in clinical development and immunology, including senior roles at Vir Biotechnology, Sonoma Biotherapeutics, FibroGen and Genentech/Roche, as well as an academic career at UCSF. In connection with his appointment, he received a stock option to purchase 47,675 shares of Jade common stock under the 2025 Stock Incentive Plan, vesting in equal monthly installments over three years and accelerating upon a change in control, subject to continued service. He will also participate in the standard non-employee director compensation program and sign the company’s standard indemnification agreement. The company issued a press release with these details.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Director stock option grant: 47,675 shares
1 metrics
Director stock option grant
47,675 shares
Option to purchase common stock under 2025 Stock Incentive Plan; vests monthly over three years
Key Terms
Class I director, non-employee director compensation program, Indemnification Agreement, change in control, +2 more
6 terms
Class I director regulatory
"appointed Mark Eisner, M.D., M.P.H., to serve as a Class I director of the Company"
A class I director is a member of a company’s board who belongs to one of several groups whose terms expire in a specified year under a staggered election system; each class is elected on a different cycle so only a portion of the board faces re-election each year. This matters to investors because it affects how quickly control of the board can change, the company’s continuity and oversight, and the ease of mounting or defending against takeover efforts—think of a team where only some players are replaced each season rather than the whole roster at once.
non-employee director compensation program financial
"eligible to receive an annual cash retainer in accordance with the Company’s non-employee director compensation program"
Indemnification Agreement regulatory
"expected to enter into the Company’s standard form of Indemnification Agreement"
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
change in control financial
"The Option will also vest in full upon a change in control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
clinical-stage biotechnology company financial
"a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases"
forward-looking statements regulatory
"may constitute “forward-looking statements” within the meaning of the federal securities laws"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
What did Jade Biosciences (JBIO) announce in its latest 8-K?
Jade Biosciences announced the appointment of Mark Eisner, M.D., M.P.H., to its Board of Directors as a Class I director. He will serve until the 2028 annual meeting and join the Nominating and Corporate Governance Committee, strengthening board-level clinical and immunology expertise.
Who is Mark Eisner and what experience does he bring to Jade Biosciences (JBIO)?
Mark Eisner is a physician-executive with over 25 years in clinical development and immunology. He held senior roles at Vir Biotechnology, Sonoma Biotherapeutics, FibroGen and Genentech/Roche, and was a Professor of Medicine and Anesthesia at UCSF, bringing deep drug-development and regulatory experience.
What equity compensation did Jade Biosciences grant to Mark Eisner?
Jade granted Dr. Eisner a stock option to purchase 47,675 shares of its common stock under the 2025 Stock Incentive Plan. The option vests in equal monthly installments over three years and fully accelerates upon a change in control, subject to his continued board service.
How long will Mark Eisner serve on the Jade Biosciences Board?
Dr. Eisner was appointed a Class I director and will serve until Jade Biosciences’ 2028 annual meeting of stockholders. He will remain in office until that meeting and until a successor is duly elected and qualified, or his earlier resignation, death, or removal.
Will Mark Eisner receive cash compensation from Jade Biosciences (JBIO)?
Yes. Dr. Eisner will be eligible for an annual cash retainer under Jade’s non-employee director compensation program. That program is described in the company’s definitive proxy statement filed April 28, 2026, and governs standard cash and equity compensation for outside directors.
What is Jade Biosciences’ business focus mentioned in the announcement?
Jade Biosciences is a clinical-stage biotechnology company developing best-in-class therapies for autoimmune diseases. Its lead candidate, JADE101, targets APRIL in immunoglobulin A nephropathy, and the pipeline includes JADE201, an anti-BAFF-R antibody, and JADE301, an undisclosed antibody program.
AI-generated analysis. How Rhea-AI works. Not financial advice.
